Journal of nephrology · 2026
The neuroimmune architecture of uremic pruritus: mechanisms and therapeutic targeting.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Corrêa Lucas Maciel de Almeida, Dante Letícia Esteves, Catenaccio Laura de Azevedo, de Oliveira Thifanny Rodrigues, Martins Beatriz Cossini Bonavita, Brandão Luiggi Kevin Virgino, Barbosa Alexandre de Assis, de Santana Gabriel Costa
Аннотация
Chronic kidney disease-associated pruritus (CKD-aP) remains a prevalent and burdensome symptom whose management is often empirical and only partially effective. Its pathophysiology appears to arise from interacting systemic, cutaneous, neural, and central mechanisms rather than from a single dominant pathway. In this review, we synthesize the evidence for a broader neuroimmune framework encompassing retained uremic solutes, microinflammation, xerosis and barrier dysfunction, immune dysregulation, neuropathic sensitization, opioid imbalance, and neuropeptide signaling. On this basis, we propose a four-node organizing model-Peripheral Neuroimmune Synapse (Node I), Neural Transmission and Hyperexcitability (Node II), Central Opioid Modulation (Node III), and Substance P/NK-1 Amplification (Node IV)-to translate mechanistic complexity into clinically intelligible domains. This model is intended as a pragmatic and hypothesis-generating framework, not as a validated endotyping system. Framed this way, it may help contextualize the observed benefits of therapies such as gabapentinoids and difelikefalin, clarify the limited performance of traditional antihistamine-based strategies, and support a more structured approach to bedside phenotyping and future enrichment-based trials. Prospective validation remains necessary before mechanism-guided therapeutic matching can be recommended as routine clinical practice.